loss

MK-2206 dihydrochloride (MK-2206 2HCl) is a variant Akt inhibitor that inhibits Akt1, Akt2, and Akt3 (IC50=8 12 65 nM) with orally active, highly potent and selective potency. MK-2206 dihydrochloride exhibits antitumor activity.

Synephrine hydrochloride (Oxedrine hydrochloride) is an agonist that acts on sympathomimetic α-adrenergic receptor (AR).

Cimicifugoside H1 shows the protective function to cerebral neuron during cerebral ischemia.

Cynoglossamine is a useful organic compound for research related to life sciences and the catalog number is T126237.

Lasioglossin-III, an antimicrobial peptide, is derived from the venom of wild bees. It exhibits significant antibacterial activity against both Gram-positive and Gram-negative bacteria, as well as antifungal and antitumor properties. Lasioglossin-III demonstrates cytotoxic effects on three cancer cell lines (HeLa S3, CRC SW 480, and CCRF-CEM T), with IC50 values of 4, 18, and 5 μM, respectively.

Loroglossin is a natural product for research related to life sciences. The catalog number is TN5834 and the CAS number is 58139-22-3.

Oxazolone is a haptenating agent that can induce models of acute or chronic colitis and atopic dermatitis. It activates Th1 Th2 responses, leading to weight loss and diarrhea, and the resulting inflammation can be alleviated by anti-IL-4 antibodies, anti-TNF-α antibodies, or IL-13R2α-Fc fusion proteins. It is also suitable for studying gene expression related to inflammatory bowel disease in zebrafish.

GSK3685032 is a non-covalent and selective DNMT1 inhibitor(IC50 = 36 nM). The inhibitory effect is time-independent and reversible. GSK3685032 induces loss of DNA methylation and transcriptional activation and inhibits cancer cell growth.

BCI hydrochloride ((E)-BCI hydrochloride) is a selective dual-specificity phosphatase 6 (DUSP6) inhibitor that inhibits RANKL-mediated osteoclastogenesis and attenuates oophorectomy-induced bone loss.BCI hydrochloride has anti-inflammatory activity, reduces reactive oxygen species (ROS) production, and partially reverses AE-induced bone loss. BCI hydrochloride has anti-inflammatory activity and can reduce reactive oxygen species (ROS) production, partially reverse AE-induced cytotoxicity, and increase ERK activity, which can be used to study inflammatory diseases.

Droloxifene (3-Hydroxytamoxifen), a tamoxifen derivative, is an oral active and selective estrogen receptor modulator.Droloxifene induced p53 expression and apoptosis in McF-7 cells.Fluroxifene has anti-estrogen and anti-implantation effects.Fluroxifene prevented bone loss in ovariectomized rats.

Soraprazan (BYK61359) is a selective potassium channel inhibitor that inhibits gastric acid secretion and ameliorates age-related eye disease by removing lipofuscin from retinal pigment epithelial (RPE) cells.

CCT020312 (0-9 µM, 24 h) treatment of medium HT29 cells for 24 h resulted in a concentration-dependent loss of P-S608-pRB signaling with linear response values between 1.8 and 6.1 µM.

Oleoylestrone (MP-101) is present in plasma and adipose tissue, has potential antioxidant effects, induces loss of body fat in rats, and can be used for weight loss.

AS-601811 is a steroidal 5α-reductase inhibitor and androgen receptor modulator used to study hair loss and acne.

Farnesyl Pyrophosphate ammonium (Farnesyl diphosphate ammonium) is a metabolic intermediate of the MVA pathway that acts as a newly identified danger signal to trigger acute cell death and induce neuronal loss in stroke.

Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stability. vutiglabridin ameliorates mptp-induced neurodegeneration in Parkinson's disease mice by targeting mitochondrial paraoxonase-2. Vutiglabridin is a clinical phase 2 drug for the treatment of obesity and has therapeutic effects on p-mitochondrial PON2 in a PD model. vutiglabridin penetrates the brain, binds PON2, and restores 1-methyl-4-phenylpyridine (MPP*)-induced neuroblastoma in SH-SY5Y Vutiglabridin significantly attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dyskinesia and dopaminergic neuronal damage in mice modeled with PD in mouse experiments.

PF-07258669 is a selective melanocortin 4 receptor (MC4) antagonist used in the study of cachexia and loss of appetite.

Navamepent (RX-10045) is an analog of resolvin E1 (a dietary-3 polyunsaturated fatty acid metabolite), which has potent anti-inflammatory activity that reduces corneal inflammation, epithelial damage, and accelerates corneal tissue repair.Navamepent inhibits the release of several key pro-inflammatory mediators from corneal epithelial cells.Navamepent is very effective against dry eye and cupping cell loss Navamepent is effective against dry eye and cupping cell loss, and accelerates tear production.

JBSNF-000028 is an orally active and potent nicotinamide N-methyltransferase (NNMT) inhibitor with inhibitory effects on human NNMT (hNNMT), monkey NNMT (mkNNMT), and mouse NNMT (mNNMT) with IC50s of 0.033 μM, 0.19 μM, and 0.21 μM, respectively.JBSNF-000028 can drive insulin sensitization and weight loss. 000028 drives insulin sensitization, glucose regulation and weight loss and can be used to study metabolic disorders.

Miclxin (DS37262926) is a novel MIC60 inhibitor that induces apoptosis through mitochondrial stress in mutant tumor cells via β-catenin.Miclxin is a potent inhibitor of mutant β-catenin, which is involved in the Wnt signaling pathway.Miclxin induces β-catenin-dependent apoptosis, leading to mitochondrial damage and loss of mitochondrial membrane. Miclxin has anti-tumor activity and kills tumors by targeting MIC60.

FiVe1 is a vimentin binding small molecule that promotes the disintegration and phosphorylation of vimentin in the metaphase, leading to mitotic disasters, polynuclearization, and loss of cancer cell dryness. FiVe1 selectively and irreversibly inhibit the growth of mesenchymal transformed breast cancer cells (FOXC2-HMLER cell, IC50=234nM) and soft tissue sarcomas of different histological subtypes.

Bupivacaine hydrochloride (Vivacaine) is a long-acting, amide-type local anesthetic. Bupivacaine hydrochloride reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization; inhibition of depolarization and nerve impulse conduction; and a reversible loss of sensation.

Tioconazole (Vagistat) is a synthetic imidazole derivative, inhibits cell wall synthesis by inhibiting the biosynthesis of ergosterol or other sterols, damaging the fungal cell membrane, altering its permeability, and promoting loss of essential intracellular elements.

Proparacaine Hydrochloride is the hydrochloride salt form of proparacaine, a benzoic acid derivative with local anesthetic property. Proparacaine hydrochloride (Proparacaine HCl) stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting sodium ion influx required for the initiation and conduction of impulses within the neuronal cell, and resulting in a loss of sensation.